Clinical trials: Cryptococcal Infection
Cryptococcal Meningitis
Efficacy of Intrathecal Administration of Liposomal Amphotericin B in Cryptococcal Meningitis
The main purpose of this study is to observe the clinical effect of intrathecal administration of liposomal amphotericin B in Cryptococcal Meningitis without Acquired Immune Deficiency Syndrome (AIDS).
- Trial name
- NCT02686853
- Testing
- Liposomal amphotericin B
- Volunteers
- 40 people
- Sponsor
- Hui Bu
Meningitis, Cryptococcal, Central Nervous System Fungal Infections
Vietnam Cryptococcal Retention in Care Study Version 1.0
It is hypothesized that implementing plasma CrAg screening in clinics providing routine HIV care will enable identification of Vietnamese adult patients with advanced HIV (CD4 ≤100 cells/μL) who have early cryptococcal disease…
- Conditions
- Meningitis, Cryptococcal, Central Nervous System Fungal Infections, Central Nervous System Infections, Meningitis, Fungal
- Trial name
- CRICS (NCT02334670)
- Testing
- Fluconazole
- Where
- Vietnam
- Volunteers
- 2,612 people
- Sponsor
- National Hospital for Tropical Diseases, Hanoi, Vietnam
Cryptococcal Meningitis
Encochleated Oral Amphotericin for Cryptococcal Meningitis Trial (EnACT)
This study is designed as two sequential trials. The first is a phase I open label trial to evaluate the safety and tolerability of MAT2203.
- Trial name
- EnACT (NCT04031833)
- Testing
- MAT2203, Amphotericin B
- Where
- Uganda
- Volunteers
- 178 people
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
Cryptococcal Meningitis, HIV Infections
Cryptococcal Optimal ART Timing Trial
The Cryptococcal Optimal ART Timing (COAT) trial seeks to determine after cryptococcal meningitis (CM) whether early initiation of antiretroviral therapy (ART) prior to hospital discharge results in superior survival compared to…
- Conditions
- Cryptococcal Meningitis, HIV Infections, AIDS
- Trial name
- COAT (NCT01075152)
- Testing
- efavirenz, nucleoside
- Where
- 3 sites in South Africa, Uganda
- Volunteers
- 177 people
- Sponsor
- University of Minnesota
Meningitis, Cryptococcal, HIV Infections
Open, Non-Comparative Study of Intravenous and Oral Fluconazole in the Treatment of Acute Cryptococcal Meningitis
To evaluate the safety and effectiveness of fluconazole as an intravenous dose as initial treatment for acute cryptococcal meningitis followed by oral therapy in AIDS and non-AIDS patients.
- Trial name
- NCT00002040
- Testing
- Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Meningitis, Cryptococcal, HIV Infections
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Maintenance Treatment for the Prevention of Relapse of Cryptococcal Meningitis in Patients With Acquired Immunodeficiency Syndrome
To compare the safety and effectiveness of fluconazole and amphotericin B as maintenance treatment for preventing the relapse of cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002074
- Testing
- Fluconazole, Amphotericin B
- Where
- 39 sites in United States, Canada
- Sponsor
- Pfizer
Cryptococcosis
Evaluation of the Association of Polymorphisms in the Innate Immune System With the Risk for Cryptococcus Neoformans Infection in Patients Not Infected With HIV and Complications Associated With Cryptococcus Neoformans Infection
Innate immunity plays an important role for fungal recognition and initiation of fungicidal activity. We hypothesize that subtle differences in different molecules of innate immunity may contribute to either the predisposition or…
- Trial name
- NCT00001701
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Meningitis, Cryptococcal, HIV Infections
A Comparison of Fluconazole and Amphotericin B in the Treatment of Cryptococcal Meningitis
To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.
- Trial name
- NCT00002305
- Testing
- Flucytosine, Fluconazole, Amphotericin B
- Where
- 45 sites in United States, Canada
- Sponsor
- Pfizer
Meningitis, Cryptococcal, HIV Infections
SCH 39304 as Therapy for Acute Cryptococcal Meningitis in HIV-Infected Patients Followed by Maintenance Therapy
To assess the safety and effectiveness of SCH 39304 as primary treatment of acute cryptococcal meningitis in HIV-infected patients.
- Trial name
- NCT00000677
- Testing
- SCH 39304
- Where
- 28 sites in United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis
Etiology, Pathogenesis, and Natural History of Idiopathic CD4+ Lymphocytopenia
Background: Idiopathic CD4+ lymphocytopenia (ICL) is a condition in which there is a decreased level of CD4+ lymphocytes (a type of white blood cell), which can lead to opportunistic infections or autoimmune disorders and…
- Conditions
- Idiopathic CD4+ Lymphocytopenia, Cryptococcal Meningitis, Warts
- Trial name
- NCT00867269
- Where
- United States
- Volunteers
- 950 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Meningitis Streptococcal, Hiv
Treatment With Tamoxifen in Cryptococcal Meningitis
The purpose of this study is to develop initial efficacy, feasibility, and safety data regarding the use of Tamoxifen in combination with amphotericin B and fluconazole in the treatment of cryptococcal meningitis.
- Conditions
- Meningitis Streptococcal, Hiv, Meningitis, Meningoencephalitis
- Trial name
- NCT03112031
- Testing
- Tamoxifen, Amphotericin B, Fluconazole
- Where
- 3 sites in Vietnam
- Volunteers
- 50 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
Cryptococcal Meningitis, Fungal Meningitis
Adjunctive Sertraline for the Treatment of HIV-Associated Cryptococcal Meningitis
This is a phase III trial to determine whether adjunctive sertraline will lead to improved survival 18-week survival. There was an initial phase I/II unmasked dose finding pharmacokinetic study of CSF concentrations in 172…
- Trial name
- ASTRO-CM (NCT01802385)
- Testing
- Sertraline
- Where
- 2 sites in Uganda
- Volunteers
- 460 people
- Sponsor
- University of Minnesota
Cryptococcal Meningitis, HIV Infections
Early Versus Delayed Antiretroviral Therapy (ART) in the Treatment of Cryptococcal Meningitis in Africa
Cryptococcal Meningitis continues to be one of the most devastating AIDS defining illness in sub-Saharan Africa. Despite the availability of azoles such as fluconazole for treatment, mortality remains high with some studies…
- Trial name
- NCT00830856
- Testing
- Fluconazole, Fixed dose - Stavudine, lamivudine and Nevirapine, Fixed dose - Stavudine, Lamivudine, Nevirapine
- Where
- Zimbabwe
- Volunteers
- 54 people
- Sponsor
- University of Zimbabwe
Neurological Disorders, Cerebral Malaria
Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC
The impact of neurological disorders is enormous worldwide, and it is increased in poor settings, due to lack of diagnosis and treatment facilities as well as delayed management.
- Conditions
- Neurological Disorders, Cerebral Malaria, Bacterial Meningitis, Central Nervous System Tuberculosis
- Trial name
- Nidiag-Neuro (NCT01589289)
- Testing
- Immunochromatographic HAT tests (DSD), Card Agglutination Trypanosoma Test, TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)
- Where
- Democratic Republic of the Congo
- Volunteers
- 352 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Cryptococcal Meningitis
Efficacy and Safety of Mycograb as Adjunctive Therapy for Cryptococcal Meningitis in Patients With AIDS
This is a multicenter, randomized, efficacy and safety trial to evaluate Mycograb®. Subjects will be randomized to one of the 3 arms: 1/ Amphotericin B (0.7 mg/kg/d) plus 5-flucytosine (100 mg /kg/d); 2/ Amphotericin B plus…
- Trial name
- NCT00847678
- Testing
- Efungumab (Mycograb), Amphotericin B, 5 flucytosine
- Where
- South Africa
- Volunteers
- 38 people
- Sponsor
- Novartis Pharmaceuticals
Cryptococcal Meningitis, HIV/AIDS
Three Induction Treatments on Cryptococcal Meningitis
Three induction treatment strategies [ voriconazole +5FC vs. amphotericin deoxycholate (0.4-0.5 mg/kg/d)+5FC vs. amphotericin deoxycholate (0.7-1.0 mg/kg/d)+5FC ] for HIV-infected patients with cryptococcal meningitis were…
- Trial name
- TITOC (NCT04072640)
- Testing
- Voriconazole 200mg, amphotericin B deoxycholate (0.4-0.5mg/kg/d), Amphotericin B-deoxycholate (0.7-1.0mg/kg/d)
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Cryptococcal Infection Disseminated
Safety Study of Fluconazole in Combination With Flucytosine for the Treatment of Early Cryptococcal Infection
The purpose of this study is to determine if treatment with two medicines in combination (fluconazole and flucytosine) is safe as compared with one medicine alone (fluconazole) for the treatment of an early infection with a…
- Trial name
- SToP-Crypto (NCT01562132)
- Testing
- Flucytosine and fluconazole, Fluconazole
- Where
- 2 sites in Kenya
- Volunteers
- 6 people
- Sponsor
- Yale University
Meningitis, Cryptococcal, HIV Infections
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002113
- Testing
- Flucytosine, Fluconazole
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
Cryptococcal Infections
Efficacy and Safety of Oral Encochleated Amphotericin B for the Treatment of Cryptococcal Infection
This will be an open label phase I/II prospective cohort study to determine the efficacy and safety of CAMB for the treatment and prevention of cryptococcal infection.
- Trial name
- ORACLE (NCT03196921)
- Testing
- Encochleated Amphotericin B
- Sponsor
- Matinas BioPharma Nanotechnologies, Inc.
AIDS-Related Opportunistic Infections, Meningo-encephalitis
Driving Reduced AIDS-associated Meningo-encephalitis Mortality
The DREAMM project is investigating whether the DREAMM interventions (1) Health system strengthening, 2) Co-designed education programs tailored to frontline healthcare workers, 3) Implementation of a diagnostic and treatment…
- Conditions
- AIDS-Related Opportunistic Infections, Meningo-encephalitis, Cryptococcal Meningitis, Bacterial Meningitis
- Trial name
- DREAMM (NCT03226379)
- Testing
- DREAMM
- Where
- 5 sites in Cameroon, Malawi and 1 more
- Volunteers
- 495 people
- Sponsor
- St George's, University of London